The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2022 | Expression of coagulation inhibitors in the immune microenvironment in precursor stages of myeloma
In this video, Xue-Yan Cui, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses her poster presentation from ISTH 2022, which focused on the expression of coagulation inhibitors in the immune microenvironment in precursor stages of multiple myeloma. Dr Cui first provides some background information on this research and comments on the high risk of thrombosis in patients with precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS). Dr Cui then discusses how the expression of coagulation inhibitors in the immune microenvironment influences disease. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.
